BIODOL Therapeutics has entered into an option agreement with KYORIN Pharmaceutical for the development and commercialization of BDT272, a pain treatment targeting FLT3, following successful Phase 1 clinical trials.

Information on the Target

BIODOL Therapeutics, known as Biodol, is a biopharmaceutical company founded in 2015 that specializes in developing innovative treatments for pain management. The company has focused its research on the FLT3 receptor, which has been identified as a significant driver of neuropathic pain. Biodol's cutting-edge research has revealed that inhibiting FLT3 signaling may eliminate opioid tolerance and hyperalgesia while maintaining analgesic effectiveness. Currently, Biodol holds an exclusive portfolio of four patents related to this promising therapeutic target.

In a recent development, Biodol has entered into an option agreement with KYORIN Pharmaceutical, a well-established Japanese pharmaceutical company dedicated to addressing unmet medical needs through innovative therapy discoveries. This collaboration is anticipated to enhance the development and commercialization of Biodol’s pain treatment candidate BDT272, following its successful completion of Phase 1 clinical trials.

Industry Overview in Japan

The pharmaceutical industry in Japan is one of the most advanced and dynamic sectors globally, characterized by significant investment in research and development. Japan ranks among the top pharmaceutical markets, driven by an a